Lyme disease vaccine Phase 2 study slated for second half of 2018

In a follow-up on the progress on French company, Valneva's Lyme disease vaccine candidate VLA15, the company expects to launch a Phase 2 study in the second half of 2018, subject to regulatory clearances, after reporting positive Phase 1 interim data for the vaccine candidate in March 2018. Phase 2 is intended to be conducted in Lyme-endemic regions in the ["]

The post Lyme disease vaccine Phase 2 study slated for second half of 2018 appeared first on Outbreak News Today.